PDUFA Dates: Investor's Guide
Every approved drug has a PDUFA date. Here's how to find them, what they mean for stock prices, and the patterns that work â and don't.
Start free with Clinical Investor âA PDUFA date (Prescription Drug User Fee Act date) is the FDA's deadline to approve, reject, or delay a drug. They are the most predictable catalysts in biotech because the date is publicly known months in advance. The stock outcome is binary and often dramatic.
What a PDUFA date actually is
When a drug company submits a New Drug Application (NDA) or Biologics License Application (BLA), the FDA charges a fee under the Prescription Drug User Fee Act and commits to a review timeline:
- Standard review: 10 months from filing acceptance
- Priority review: 6 months from filing acceptance
- Breakthrough Therapy designation: usually combined with priority review
The PDUFA date is when the FDA must respond. It can: (a) approve, (b) issue a Complete Response Letter (CRL â "no, here's what to fix"), (c) extend the review with a major amendment, or (d) approve with REMS (risk-mitigation requirements).
How PDUFA dates affect stock prices
| Outcome | Typical stock reaction (small/mid-cap biotech) |
|---|---|
| Approval, no surprises | +10% to +50% |
| Approval with broader label than expected | +30% to +200% |
| Approval with narrower label or REMS | â10% to +20% (often a "sell-the-news" reaction) |
| Complete Response Letter (CRL) | â30% to â80% |
| PDUFA delay (review extension) | â10% to â30% |
How to find upcoming PDUFA dates
- Clinical Investor catalyst calendar â curated PDUFA dates with company tickers, indication, and pre-event analyst commentary
- FDA Drug Approvals page â official, lagging, no upcoming dates
- Company 10-Q / 10-K filings â typically disclose target PDUFA dates in pipeline tables
- SEC 8-K filings â material PDUFA-date changes (extensions) require disclosure
- BioPharma Catalyst, Stock Catalysts â paid services with similar coverage
Trading patterns around PDUFA dates
Some patterns hold up; others are mostly noise:
- Run-up: Stocks often rally 10-30% in the 30 days before a high-profile PDUFA, especially if the drug had positive Phase 3 data. Mean-reverts ~50% of the time on the actual decision.
- Implied volatility: Options around PDUFA dates have very high IV. Selling premium has favorable risk/reward IF you have a view on the binary outcome.
- "Sell the news" pattern: Approvals with narrower-than-expected labels often see initial pop, then 5-15% decline in following days as analysts cut estimates.
- CRL recovery: Stocks that drop 50%+ on a CRL often recover 30-100% within 12 months IF the issues are addressable. Worth screening.
Get the catalyst calendar + Trial Translator
Free tier: weekly catalyst briefing, basic company profiles. Premium ($19/mo): real-time alerts, unlimited Trial Translator, deep dives.
Start free âFrequently Asked Questions
- What does PDUFA stand for?
- Prescription Drug User Fee Act. Originally passed in 1992, it allows the FDA to charge user fees to drug sponsors in exchange for committing to specific review timelines.
- Can a PDUFA date be missed?
- Yes â the FDA misses ~5-10% of PDUFA dates, usually by 2-4 weeks. Major delays (more than 90 days) usually trigger SEC disclosure and stock reaction.
- What's the difference between PDUFA and AdCom?
- PDUFA = the FDA's deadline to decide. AdCom (Advisory Committee meeting) = a public meeting of outside experts who recommend (but do not bind) the FDA decision. Many PDUFAs do NOT have an AdCom; AdComs typically happen 2-4 months before PDUFA when held.
- Is buying biotech stocks before PDUFA dates a good strategy?
- It's a binary bet with substantial downside. Professional approach: position-size such that a CRL doesn't sink your portfolio, and only buy when you have a differentiated view on probability of approval.
Related guides
Educational only. Not investment advice. Biotech investing carries substantial risk; consult a licensed advisor.